Shan Dong Kexing Bioproducts Co (SHSE:688136) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shan Dong Kexing Bioproducts Co EBITDA Margin % Related Terms
Shan Dong Kexing Bioproducts Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co EBITDA Margin % Chart
SHSE:688136 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shan Dong Kexing Bioproducts Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shan Dong Kexing Bioproducts Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co (SHSE:688136) has a EBITDA Margin % of -5.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. According to the industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #239 out of 939 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Shan Dong Kexing Bioproducts Co's EBITDA Margin % too high?
Shan Dong Kexing Bioproducts Co's current EBITDA Margin % is -5.49%. Based on the distribution chart, Shan Dong Kexing Bioproducts Co ranks #239 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shan Dong Kexing Bioproducts Co has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shan Dong Kexing Bioproducts Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #239 out of 939 companies for EBITDA Margin %. This puts Shan Dong Kexing Bioproducts Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. Shan Dong Kexing Bioproducts Co's current EBITDA Margin % is -5.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shan Dong Kexing Bioproducts Co stock overvalued right now?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co (SHSE:688136) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.99, compared to a current price of ¥20.84 — trading 13.1% below its estimated fair value. The current EBITDA Margin % is -5.49%. Shan Dong Kexing Bioproducts Co's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shan Dong Kexing Bioproducts Co (SHSE:688136), the current EBITDA Margin % is -5.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shan Dong Kexing Bioproducts Co (SHSE:688136) Overvalued in 2026?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co stock appears to be undervalued.
The current stock price of ¥20.84 is trading 13.1% below its estimated GF Value™ of ¥23.99.
GuruFocus considers Shan Dong Kexing Bioproducts Co to be Modestly Undervalued.
Key valuation signals for SHSE:688136:
EBITDA Margin %: -5.49%
GF Value™: ¥23.99 vs. price of ¥20.84 (13.1% below fair value)
No single metric tells the full story. See the SHSE:688136 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shan Dong Kexing Bioproducts Co Business Description
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
44GF Score
Get the complete analysis for SHSE:688136
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688136 has been successfully added to your 
